Study shows no benefit of Isentress in reducing low-levels of HIV
스크롤 이동 상태바
Study shows no benefit of Isentress in reducing low-levels of HIV
기자명
메디칼라이터팀
입력 2009.07.24 00:00
수정 2009.07.24 09:35
댓글 0
According to research presented at the International AIDS Society conference, Merck & Co."s Isentress [raltegravir] failed to reduce low-level reservoirs of HIV. A study was done on patients whose viral levels were almost undetectable for 6 months while using standard antivirals. Participants had a 12 week course of Isentress or placebo then a further 12 week course of an alternate therapy. No difference in low levels were detected using highly sensitive tests.